Talk:Amphetamine: Difference between revisions
imported>Michael MacNeil (Added article checklist.) |
Pat Palmer (talk | contribs) m (Text replacement - "[[United States|" to "[[United States of America|") |
||
(3 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
{{ | {{subpages}} | ||
NOTE: The <code><nowiki>{{editintro}}</nowiki></code> template atop the article page should be removed prior approval. | |||
}} | |||
<!-- DO NOT ARCHIVE ABOVE THIS LINE --> | |||
==Cleanup== | ==Cleanup== | ||
Inexistant drugbox moved from the main space. To reconsider, whether it pays for itself. | Inexistant drugbox moved from the main space. To reconsider, whether it pays for itself. | ||
Line 29: | Line 22: | ||
| elimination_half-life= 10–13 hours | | elimination_half-life= 10–13 hours | ||
| excretion = [[Renal]]; significant portion unaltered | | excretion = [[Renal]]; significant portion unaltered | ||
| pregnancy_category = C ([[United States|USA]]) | | pregnancy_category = C ([[United States of America|USA]]) | ||
| legal_status = [[Drug Enforcement Administration|DEA]] Schedule II ([[United States|USA]])<br>Class B ([[United Kingdom|UK]])<br>Schedule III ([[Controlled Drugs and Substances Act|Canada]]) | | legal_status = [[Drug Enforcement Administration|DEA]] Schedule II ([[United States of America|USA]])<br>Class B ([[United Kingdom|UK]])<br>Schedule III ([[Controlled Drugs and Substances Act|Canada]]) | ||
| routes_of_administration= Oral, [[Intravenous infusion|Intravenous]], [[Vaporize]]d, [[Insufflate]]d, [[Suppository]] | | routes_of_administration= Oral, [[Intravenous infusion|Intravenous]], [[Vaporize]]d, [[Insufflate]]d, [[Suppository]] | ||
}} | }} | ||
I would like to make this article a little more readable and a little less complacent about recreational drug use of amphetamine, which is a major drug of abuse. [[User:Nancy Sculerati|Nancy Sculerati]] 15:46, 31 March 2007 (CDT) | I would like to make this article a little more readable and a little less complacent about recreational drug use of amphetamine, which is a major drug of abuse. [[User:Nancy Sculerati|Nancy Sculerati]] 15:46, 31 March 2007 (CDT) | ||
Also, to make it accurate from a medical standpoint. For example, a current indication for amphetamine is to help rehabilitate patients with traumatic brain injury who have depressed conciousness-not mentioned at all here. will add references below, for discussion and for article. [[User:Nancy Sculerati|Nancy Sculerati]] 17:04, 31 March 2007 (CDT) | Also, to make it accurate from a medical standpoint. For example, a current indication for amphetamine is to help rehabilitate patients with traumatic brain injury who have depressed conciousness-not mentioned at all here. will add references below, for discussion and for article. [[User:Nancy Sculerati|Nancy Sculerati]] 17:04, 31 March 2007 (CDT) |
Latest revision as of 13:57, 2 February 2023
NOTE: The {{editintro}}
template atop the article page should be removed prior approval.
Cleanup
Inexistant drugbox moved from the main space. To reconsider, whether it pays for itself. Template:Drugbox
I would like to make this article a little more readable and a little less complacent about recreational drug use of amphetamine, which is a major drug of abuse. Nancy Sculerati 15:46, 31 March 2007 (CDT) Also, to make it accurate from a medical standpoint. For example, a current indication for amphetamine is to help rehabilitate patients with traumatic brain injury who have depressed conciousness-not mentioned at all here. will add references below, for discussion and for article. Nancy Sculerati 17:04, 31 March 2007 (CDT)
Annotated references
Srisurapanont M. Jarusuraisin N. Kittirattanapaiboon P. Treatment for amphetamine withdrawal. [Review] [21 refs] [Journal Article. Review] Cochrane Database of Systematic Reviews. (4):CD003021, 2001. UI: 11687170
Shippenberg TS. Chefer VI. Zapata A. Heidbreder CA. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. [Review] [73 refs] [Journal Article. Review] Annals of the New York Academy of Sciences. 937:50-73, 2001 Jun.
UI: 11458540
ones S. Gutlerner JL. Addictive drugs modify excitatory synaptic control of midbrain dopamine cells. [Review] [50 refs] [Journal Article. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.. Review] Neuroreport. 13(2):A29-33, 2002 Feb 11. UI: 11893925
Niculescu AB 3rd. Kelsoe JR. Convergent functional genomics: application to bipolar disorder. [Review] [33 refs] [Journal Article. Review] Annals of Medicine. 33(4):263-71, 2001 May. UI: 11405548
Dekhuijzen PN. Machiels HA. Heunks LM. van der Heijden HF. van Balkom RH. Athletes and doping: effects of drugs on the respiratory system.[see comment]. [Review] [90 refs] [Journal Article. Research Support, Non-U.S. Gov't. Review] Thorax. 54(11):1041-6, 1999 Nov. UI: 10525566
Chaudhuri C. Salahudeen AK. Massive intracerebral hemorrhage in an amphetamine addict. [Review] [23 refs] [Case Reports. Journal Article. Review] American Journal of the Medical Sciences. 317(5):350-2, 1999 May. UI: 10334124
Berger PA. Biochemistry and the schizophrenia. Old concepts and new hypothesis. [Review] [110 refs] [Journal Article. Research Support, U.S. Gov't, P.H.S.. Review] Journal of Nervous & Mental Disease. 169(2):90-9, 1981 Feb. UI: 7009786
Badiani A. Robinson TE. Drug-induced neurobehavioral plasticity: the role of environmental context.[see comment]. [Review] [146 refs] [Journal Article. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.. Review] Behavioural Pharmacology. 15(5-6):327-39, 2004 Sep. UI: 15343056
appetite
Pirisino R. Galeotti N. Livi S. Raimondi L. Ghelardini C. 4-methyl benzylamine stimulates food consumption and counteracts the hypophagic effects of amphetamine acting on brain Shaker-like Kv1.1 channels. [Journal Article. Research Support, Non-U.S. Gov't] British Journal of Pharmacology. 147(2):218-24, 2006 Jan. UI: 16284626
attention deficit disorder
Dopheide JA. ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients. [Journal Article] American Journal of Health-System Pharmacy. 62(14):1502-9, 2005 Jul 15. UI: 15998933(excerpt from abstract: Strong evidence from controlled clinical trials in elementary-school-age children supports the superior efficacy of stimulant therapy over nonpharmacologic interventions.4–7 Atomoxetine and bupropion are considered second-line agents and have been effective in placebo-controlled trials. Their use may be appropriate in select patients.8,9 Tricyclic antidepressants are considered second- or third-line agents because of the risk of toxicity, while clonidine and guanfacine should be considered fourth-line or as adjunctive treatment because of the lack of established efficacy as monotherapy.9,10 (excerpt from article:Several reviews and meta-analyses document the short-term efficacy of methylphenidate, dexmethylphenidate, dextroamphetamine, mixed amphetamine salts, and pemoline in reducing the core symptoms of inattention, impulsivity, and hyperactivity associated with ADHD (Table 1).2,7,20 Sixty to eighty percent of adolescents and adults and at least 80% of children will respond to stimulants when initiated and adjusted appropriately. There is no evidence showing that one stimulant has superior efficacy over another. Because of the risk of hepatotoxicity, pemoline should be used only if all other stimulant and nonstimulant preparations are ineffective.7,9,10
dopamine
Sekine Y. Ouchi Y. Takei N. Yoshikawa E. Nakamura K. Futatsubashi M. Okada H. Minabe Y. Suzuki K. Iwata Y. Tsuchiya KJ. Tsukada H. Iyo M. Mori N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. [Comparative Study. Journal Article. Research Support, Non-U.S. Gov't] Archives of General Psychiatry. 63(1):90-100, 2006 Jan. UI: 16389202
production of apparent psychosis
Krystal JH. Perry EB Jr. Gueorguieva R. Belger A. Madonick SH. Abi-Dargham A. Cooper TB. Macdougall L. Abi-Saab W. D'Souza DC. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. [Clinical Trial. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, Non-P.H.S.. Research Support, U.S. Gov't, P.H.S.] Archives of General Psychiatry. 62(9):985-94, 2005 Sep. UI: 16143730
Gerber DJ. Tonegawa S. Psychotomimetic effects of drugs--a common pathway to schizophrenia?. [Journal Article] New England Journal of Medicine. 350(10):1047-8, 2004 Mar 4. UI: 14999118
characteristics of amphetamine abuse
increased HIV (+) rate
Buchacz K. McFarland W. Kellogg TA. Loeb L. Holmberg SD. Dilley J. Klausner JD. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. [Journal Article] AIDS. 19(13):1423-4, 2005 Sep 2. UI: 16103774
- Article with Definition
- Developing Articles
- Nonstub Articles
- Internal Articles
- Chemistry Developing Articles
- Chemistry Nonstub Articles
- Chemistry Internal Articles
- Health Sciences Developing Articles
- Health Sciences Nonstub Articles
- Health Sciences Internal Articles
- Chemistry Underlinked Articles
- Underlinked Articles
- Health Sciences Underlinked Articles